At a glance
ClinicalIndex Comparison RecordN/ARecruiting· 330 target
Drug / intervention
Escalated: Inhomogeneous dose plan +1 moreradiation
Likely dose
Not stated in record
Key inclusion· 5
- ✓Histologically or cytologically confirmed locally advanced NSCLC stage IIB to IIIB
- ✓Able to comply with treatment and follow-up procedures
- ✓Negative pregnancy test (women)
- ✓Signed informed consent
Key exclusion· 7
- ✕Any unstable systemic disorder including infection, unstable angina, congestive heart failure, severe liver, kidney or metabolic disease
- ✕Need for nasal oxygen
- ✕Prior thoracic radiotherapy with significant overlap with previous fields
- ✕Any other active malignant disease
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Novel Approach to Radiotherapy in Locally Advanced Lung Cancer - Heterogeneous FDG-guided Dose Escalation With Concomitant Navelbine®
In Brief
A clinical study evaluating Escalated: Inhomogeneous dose plan and Standard: Homogeneous dose plan for NSCLC. Currently recruiting, targeting 330 participants across 7 sites.
Detailed Summary
To investigate the effect of escalation of radiation dose to tumor and lymph nodes based on an inhomogeneous dose distribution controlled by FDG-PET positive areas compared to a standard homogeneous dose spread
Study Details
Timeline
N/ARecruiting
2015201620172018201920202021202220232024202520262027202820292030
Enrollment StartJan 2015
First PostedFeb 2015
TodayJul 2026
Primary CompletionOct 2029
First PostedFeb 3, 2015
Enrollment StartJan 1, 2015
Primary CompletionOct 1, 2029
TodayJul 2, 2026
Enrollment to primary: 14.8 yearsPosted 11.4 years agoPrimary completion in 3.2 years
Interventions
Escalated: Inhomogeneous dose planradiation
Standard: Homogeneous dose planradiation